首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   162353篇
  免费   15452篇
  国内免费   9666篇
耳鼻咽喉   1271篇
儿科学   2091篇
妇产科学   1811篇
基础医学   23502篇
口腔科学   2874篇
临床医学   19683篇
内科学   22729篇
皮肤病学   1792篇
神经病学   7922篇
特种医学   5559篇
外国民族医学   68篇
外科学   15704篇
综合类   26684篇
现状与发展   33篇
一般理论   18篇
预防医学   11582篇
眼科学   3947篇
药学   18294篇
  143篇
中国医学   9032篇
肿瘤学   12732篇
  2024年   643篇
  2023年   2518篇
  2022年   6491篇
  2021年   8179篇
  2020年   5973篇
  2019年   5268篇
  2018年   5580篇
  2017年   5067篇
  2016年   4842篇
  2015年   7036篇
  2014年   8634篇
  2013年   8501篇
  2012年   11959篇
  2011年   12687篇
  2010年   8919篇
  2009年   7261篇
  2008年   8819篇
  2007年   8818篇
  2006年   8096篇
  2005年   7265篇
  2004年   5688篇
  2003年   5538篇
  2002年   4743篇
  2001年   3906篇
  2000年   3441篇
  1999年   3025篇
  1998年   1901篇
  1997年   1986篇
  1996年   1406篇
  1995年   1369篇
  1994年   1217篇
  1993年   834篇
  1992年   1094篇
  1991年   990篇
  1990年   870篇
  1989年   796篇
  1988年   724篇
  1987年   628篇
  1986年   578篇
  1985年   467篇
  1984年   405篇
  1983年   325篇
  1982年   286篇
  1981年   242篇
  1980年   213篇
  1979年   229篇
  1978年   201篇
  1977年   227篇
  1976年   200篇
  1974年   161篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
European Archives of Oto-Rhino-Laryngology - Several polymorphisms in a disintegrin and metalloproteinase 33 (ADAM33) have been implicated in susceptibility to allergic rhinitis (AR), but the...  相似文献   
3.
BACKGROUNDGuillain-Barré syndrome (GBS) is a rare disorder that typically presents with ascending weakness, pain, paraesthesias, and numbness, which mimic the findings in lumbar spinal stenosis. Here, we report a case of severe lumbar spinal stenosis combined with GBS.CASE SUMMARYA 70-year-old man with a history of lumbar spinal stenosis presented to our emergency department with severe lower back pain and lower extremity numbness. Magnetic resonance imaging confirmed the diagnosis of severe lumbar spinal stenosis. However, his symptoms did not improve postoperatively and he developed dysphagia and upper extremity numbness. An electromyogram was performed. Based on his symptoms, physical examination, and electromyogram, he was diagnosed with GBS. After 5 d of intravenous immunoglobulin (0.4 g/kg/d for 5 d) therapy, he gained 4/5 of strength in his upper and lower extremities and denied paraesthesias. He had regained 5/5 of strength in his extremities when he was discharged and had no symptoms during follow-up.CONCLUSIONGBS should be considered in the differential diagnosis of spinal disorder, even though magnetic resonance imaging shows severe lumbar spinal stenosis. This case highlights the importance of a careful diagnosis when a patient has a history of a disease and comes to the hospital with the same or similar symptoms.  相似文献   
4.
Synovial chondromatosis is a rare lesion in the wrist, but some cases in the distal radioulnar joint have been reported and previous case reports emphasize joint calcifications, shown on preoperative plain radiographs. We report an extremely uncommon case of synovial chondromatosis in the pisotriquetral joint, in which radiographs and magnetic resonance imaging did not demonstrate apparent calcified bodies. In our case, for the accurate diagnosis and treatment, surgical exploration of the joint and synovectomy with removal of loose bodies was performed.  相似文献   
5.
6.
7.
Lessons Learned
  • The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
  • Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
  • The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
BackgroundThe RAS/RAF/MEK/ERK signaling pathway is associated with proliferation and progression of hepatocellular carcinoma (HCC). Preclinical data suggest that paradoxical activation of the MAPK pathway may be one of the resistance mechanisms of sorafenib; therefore, we evaluated trametinib plus sorafenib in HCC.MethodsThis was a phase I study with a 3+3 design in patients with treatment‐naïve advanced HCC. The primary objective was safety and tolerability. The secondary objective was clinical efficacy.ResultsA total of 17 patients were treated with three different doses of trametinib and sorafenib. Two patients experienced dose‐limiting toxicity, including grade 4 hypertension and grade 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin over 7 days. Maximum tolerated dose was trametinib 1.5 mg daily and sorafenib 200 mg twice a day. The most common grade 3/4 treatment‐related adverse events were elevated AST (37%) and hypertension (24%). Among 11 evaluable patients, 7 (63.6%) had stable disease with no objective response. The median progression‐free survival (PFS) and overall survival (OS) were 3.7 and 7.8 months, respectively. Phosphorylated‐ERK was evaluated as a pharmacodynamic marker, and sorafenib plus trametinib inhibited phosphorylated‐ERK up to 98.1% (median: 81.2%) in peripheral blood mononuclear cells.ConclusionTrametinib and sorafenib can be safely administered up to trametinib 1.5 mg daily and sorafenib 200 mg twice a day with limited anticancer activity in advanced HCC.  相似文献   
8.
目的 探讨剂量组学在预测肺癌根治性放疗患者放射性肺炎发生中的应用潜能。方法 回顾性收集行根治性放疗的314例肺癌患者的临床资料、放疗剂量文件、定位及随访CT图像,根据临床资料及影像学随访资料对放射性肺炎进行分级,提取全肺的剂量组学特征,构建机器学习模型。应用1000次自助抽样法(bootstrap)的最小绝对值收敛和选择算子嵌套逻辑回归(LASSO‐LR)及1000次bootstrap的赤池信息量准则(AIC)向后法筛选与放射性肺炎相关的剂量组学特征,随机按照7∶3划分为训练集及验证集,应用逻辑回归建立预测模型,并应用ROC曲线及校正曲线评价模型的性能。结果 共提取120个剂量组学特征,经LASSO‐LR降维筛选得到12个特征进入“特征池”,再经过AIC向后法筛选,最终筛选出6个剂量组学特征进行模型构建,训练集AUC为0.77(95%CI为0.65~0.87),独立验证集AUC为0.72(95%CI为0.64~0.81)。结论 利用剂量组学建立的预测模型具有预测放射性肺炎发生的潜力,但仍需继续纳入多中心数据及前瞻性数据进一步挖掘剂量组学的应用潜能。  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号